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Background: Alterations of the APP pathway or DNA damage induce neuronal cell death.
Results: Alterations of the APP pathway or DNA damage increase TAp73 expression and reduce Np73 protein levels.
Conclusion: A tight control of the expression of p73 isoforms participates in neuronal cell death.
Significance: p73 isoforms may play a role in neurodegenerative diseases such as Alzheimer and in the neurotoxicity of
anticancer drug therapies.
Genetic ablations of p73 have shown its implication in the
development of the nervous system. However, the relative con-
tribution of Np73 and TAp73 isoforms in neuronal functions
is still unclear. In this study, we have analyzed the expression of
these isoforms during neuronal death induced by alteration of
the amyloid- precursor protein function or cisplatin. We
observed a concomitant up-regulation of aTAp73 isoform and a
down-regulation of a Np73 isoform. The shift in favor of the
pro-apoptotic isoform correlated with an induction of the p53/
p73 target genes such as Noxa. At a functional level, we showed
that TAp73 induced neuronal death and that Np73 has a neu-
roprotective role toward amyloid-precursorprotein alteration
or cisplatin.We investigated the mechanisms of p73 expression
and found that the TAp73 expression was regulated at the pro-
moter level. In contrast, regulation ofNp73 protein levels was
regulated by phosphorylation at residue 86 and multiple pro-
teases. Thus, this study indicates that tight transcriptional and
post-translational mechanisms regulate the p73 isoform ratios
that play an important role in neuronal survival.
Given that over 50% of human tumors exhibit mutations or
inactivation of p53 (1), this gene has been extensively studied
for its major role in tumor suppression. DNA damage, onco-
gene activation, and also various other cellular stresses
(hypoxia, radical oxidized species production, etc.) increase p53
protein levels leading to cell growth arrest or apoptosis through
up-regulation of its target genes (p21, Bax, GADD 45,MDM2,
or DR5 (2)). Beside its tumor suppressor gene function, p53
plays a role in other physiological or pathological situations. In
the nervous system, p53 has been shown to participate in ter-
minal neuronal maturation as well as neuronal apoptosis (3–9).
Importantly, p53 activation has been observed in various neu-
rodegenerative diseases, such as ALS, Alzheimer, Parkinson,
and Angelman syndrome (9–15). However, the signaling path-
ways leading to p53 activation or the target genes of p53 in
neurons have never been documented.
More recently, p63 and p73, two homologs of p53, have been
identified (16). Similarly to p53, these genes play important
roles in the embryonic development of various organs (brain,
skin, limb, immune system, etc.). In particular, p73/ mice
exhibit defects in the nervous system, notably in the hippocam-
pus and the olfactory bulbs (17). Analysis of the contribution of
p73 to neuronal differentiation and apoptosis is complicated by
the existence of multiple isoforms. These isoforms vary in their
C terminus due to alternative splicing (TAp73, -, -, and -)
or in their N terminus due to alternate promoter usage that
skips an N-terminal transactivation domain (Np73 and -)
(18, 19). TAp73s are transcription factors with positive or neg-
ative effects on gene expression (20, 21). Np73 isoforms,
which lack the N-terminal transactivation domain (TA),6 were
shown to exert a dominant inhibitory effect on the full-length
isoforms. TAp73 isoforms induce neuronal differentiation in
SYH5 cells (22) and participate in oligodendrocyte differentia-
tion (23). Np73 isoforms favor neuronal survival (24, 25).
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More recently, a complex regulation of p73 and p63 has also
been identified in cortical neurons following ischemia, with
TAp73 being down-regulated while TAp63 is induced (26).
Neuronal apoptosis has been proposed to be a part of the
processes involved in neurodegenerative diseases, such as ALS,
Alzheimer, Parkinson, or evenneuropathy following anticancer
treatments. Alzheimer disease is characterized by the patholog-
ical accumulation of amyloid- plaques resulting from muta-
tions in the amyloid- precursor protein (APP) or the -secre-
tases, PS1 and PS2. Interestingly, p73 expression is increased in
neurons from Alzheimer patients, and the TAp73 isoforms are
induced by treatmentwith the amyloid-peptide (27, 28). It has
also recently been shown that the deletion of the p73 gene
favors neuronal aging and the appearance of Tau phosphoryla-
tion, a characteristic of Alzheimer disease (29). These studies
suggest that p73may be playing a role in the neuronal apoptosis
induced by alteration of the APP processing.
To clarify the role of the p73 gene in the regulation of the
balance between survival and apoptosis in neurons, we under-
took a comparative study of the TAp73 and Np73 isoforms in
primary cultures of neurons submitted to activation of the
-amyloid polypeptide precursor and cisplatin, a DNA-damag-
ing drug. Using these models, we previously showed a regula-
tion of MDMX and MDM2, two proteins that control p53 and
p73 activity (30). The data obtained here clearly indicate that
both p73 isoforms exert opposite effects on neuronal survival.
Furthermore, we found that the ratio between the two types of
isoforms was altered by a variety of neurotoxic insults, includ-
ing the activation of the APP pathway. Transcriptional and
post-transcriptionalmechanisms contribute to tight regulation
of this ratio, critical for neuronal survival.
EXPERIMENTAL PROCEDURES
Cell Culture—Cortical neurons were dissected from E16
murine embryos as described previously (30). Briefly, after
enzymatic and mechanical dissociation, cells were plated at a
density of 500 cells/mm2 on 0.1mg/ml polyornithine precoated
culture dishes and were grown at 37 °C in a humidified atmo-
sphere (5% CO2, 95% air). Plating culture medium contained
Dulbecco’smodified Eagle’smedium (DMEM; Invitrogen) sup-
plementedwith 10%heat-inactivated horse serum (Invitrogen),
100 nM insulin (Invitrogen), and 50 mg/ml gentamycin (Invit-
rogen). 48 h after plating, cells were switched to defined
medium containing DMEM supplemented with 10 nM insulin,
100mg/ml human transferrin, 60mMputrescine, 30 nM sodium
selenite, and 50 mg/ml gentamycin. Neurons were considered
as immature up to 2 days after plating and asmature 5 days after
plating. N2A cells were obtained from the ATCC and grown in
DMEM with 10% fetal bovine serum.
ColorimetricMTTAssay—Cells were cultured in 96-well cul-
ture dishes (Costar). A modified procedure of the original
method (31) was used tomeasuremitochondrial activity (MTT
assay) as described previously (32). Briefly, cultures were rinsed
with DMEM and incubated for 1 h at 37 °C in freshly prepared
culture medium containing 0.5 mg/ml of MTT (Sigma).
Mediumwas then removed, and dark blue crystals formed dur-
ing reaction were dissolved by adding 100l/well of 0.04 MHCl
in isopropyl alcohol. Plates were stirred at room temperature to
ensure that all crystals were dissolved and read on a Bio-Rad
680 micro-ELISA plate reader, using a test wavelength of 490
nm and a nonspecific wavelength of 650 nm for background
absorbency. Results are given as percentage of survival, taking
cultures grown in HK medium as 100%.
Expression Vectors, Reporter Genes, and siRNA—HA-
TAp73 and HA-Np73 expression vectors were described
previously (33). pCMVcyclinA, pCMVcyclinD, pCMVCDK4,
and pCMV CDK5 expression vector were a gift from Dr. K.
Okamoto (Cancer Center, Tokyo). pCMV HA-JNK was kindly
provided by Dr. Ron Prywes. pcDNA constructs encoding
CDK1 or CDK2 proteins were a gift fromDr. S. van denHeuvel.
pCMV-HA Np73 T86A was generated using the Stratagene
PCRmutagenesis kit. CMVwild typeAPP, APPKM670/671NL
(APPSW), AICD, PS1, and PS1 A79V (PS1t) were generated
by RT-PCR and subcloned in pcDNA3 vector and site-directed
mutagenesis. pBax-Luc has been described (34). pBax-min-Luc
was kindly provided by Dr. C. DiComo (Aureon Biosciences)
and contains a duplex oligonucleotide encoding the p53-re-
sponsive cis-acting element from bax, cloned upstream from
the minimal c-fos promoter (53 to 42) in pGL3-OFLUC.
The DR5 promoter reporter plasmid was obtained from Dr. T.
Sakai (Kyoto, Japan). The Noxa luciferase construct was a gen-
erous gift of Dr. Tanigushi (Tokyo, Japan).
Stealth siRNA annealed duplexes were obtained from
Invitrogen and targeted the following 5 to 3 DNA se-
quences: siTAp73#1, GCCATCCGAAACACCAATGAG-
TACA; siTap73#2, GCAGGAAAGGACTCATGAAATCATA;
siCt, sequence control GC 50% (Invitrogen). Cotransfection
experiments with siRNA and GFP-expressing plasmid were
performed as described previously (35).
Transfection and Luciferase Assays—Cells were transfected
by a polyethyleneimine-based protocol as described previously
(36). Cells were grown inDMEM, 10%FBS and transfectedwith
various amounts of DNA. DNA and polyethyleneimine (0.33l
of 0.1 M/g DNA) were mixed and added to the cells. Plates
were centrifuged at 1500 rpm for 5 min and placed in the incu-
bator for 1 h, after which fresh medium was added. For lucifer-
ase assays, cells were seeded in 12-well, 3.8-cm2 plates and
transfectedwith the expression vectors (200 ng of each) and the
reporter constructs (250 ng of each). Luciferase activity was
measured in each well 24 h later, and results were normalized
with a CMV-driven reporter gene.
Transfection and Apoptosis Assay—Neurons were grown on
coverslips coated with polyornithine in 24-well plates. Cells
were cotransfected with the expression vectors (200 ng/well),
siRNA (50 nM), and the GFP expression vector (50 ng/well) as
described previously (35). Cellswere treated or not for 18 hwith
the neurotoxic agents. The cells were then washed with PBS
and fixed with 4% paraformaldehyde for 15 min. After two
washes, cells were incubated for 10minwith theHoechst nuclei
staining agent (1g/ml). GFP-positive cells were then observed
with a microscope to assess the morphology of the nuclei and
the neurites.
Preparation of Whole Cell Extracts and Immunoblotting—
Neurons were lysed as described previously (37) in 150 l of
lysis buffer (TEGN: 20 mM Tris-HCl, pH 8, 1 mM EDTA, 0.5%
Nonidet P-40, 150mMNaCl, 1mMDTT, 10% glycerol, protease
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inhibitors (Sigma)), sonicated for 30 s, and centrifuged at
13,000 rpm for 12 min. Protein concentrations were deter-
mined using a colorimetric assay (Bio-Rad). Sample buffer (38)
was added to 20–75g of proteins, and samples were heated to
95 °C for 3 min followed by electrophoresis through a 10%
SDS-polyacrylamide gel. Proteins were transferred to nitrocel-
lulose membranes (Schleicher & Schuell) and visualized by
enhanced chemiluminescence detection (Amersham Biosci-
ences). CO73A and TA73Awere produced and purified using a
differential purificationwith peptides located in theN-terminal
part and in the core domain. Baxwas detectedwith the anti-Bax
(N20; Santa Cruz Biotechnology, 1:2000) and DR5 with the
anti-DR5 (M20; Santa Cruz Biotechnology, 1:200) antibodies.
Actin detection was done with an anti-actin antibody from Dr.
Aunis (Strasbourg, France).
Immunopurification of p73 Proteins, in Vitro Phosphoryla-
tion, and Degradation Assays—Neurons or N2A cells were
plated in 6-cm diameter plates and treated in duplicates or trip-
licates subsequently mixed. N2A cells were transfected with
Np73 expression vectors, and after 48 h cells were harvested.
Cells were lysed in 100 l of lysis buffer (TEGN: 20 mM Tris-
HCl, pH 8, 1 mM EDTA, 0.5% Nonidet P-40, 150 mM NaCl, 1
mM DTT, 10% glycerol, 5 mM PMSF, 100 M benzamidine, 300
g/ml leupeptin, 10 g/ml bacitracin, 100 g/ml, -macro-
globulin, and phosphatase inhibitors (cocktails I and II,
Sigma)), and the extracts were centrifuged at 13,000 rpm for 12
min to remove cell debris. p73 proteins (400–750 g of whole
cell extract) were immunoprecipitated at 4 °C for 3 h with 30l
of 50% slurry protein A-Sepharose beads cross-linked to an
anti-HA antibody (12CA5) or with a mixture of protein A-Sep-
harose beads and anti-pan p73 antibody. After incubation, the
samples were washed four times with 1 ml of wash buffer (20
mM Tris-HCl, pH 8, 150 mM NaCl, 1 mM EDTA, 0.5% Nonidet
P-40, 1 mM DTT, 10% glycerol). For immunoblotting, the
excess of liquid was aspirated, and 35 l of sample buffer was
added to the beads before heating at 95 °C for 3 min. After
centrifugation (3 min at 13,000 rpm), samples were separated
by electrophoresis through 10% SDS-PAGE. For in vitro phos-
phorylation, dried beads were resuspended in 40 l of kinase
reaction mixture containing radioactive -ATP and the immu-
nopurified cyclin A-CDK1 complex. After a 30-min incubation
period at 37 °C, beads were washed, resuspended in sample
buffer, heated, and loaded on a 10% SDS-PAGE. For in-tube
degradation assay, immunoprecipitation of Np73 proteins
was done in the absence of protease inhibitors, and purified p73
proteins were incubated 2 h with extracts from neurons pre-
pared in TEGN buffer in the absence of protease inhibitors.
After electrophoresis, proteins were transferred to nitrocellu-
lose membranes (Schleicher & Schuell). For HA detection, the
16B12 monoclonal HA antibody (Babco, 1 mg/ml) was used at
1:1000. Thr-86 phosphorylation was followed by an antigen-
purified phospho-Thr-86 p73 rabbit polyclonal antibody used
at a dilution of 1:1000 (33). p73 detection was performed with
themousemonoclonal ER15 (New England Biolabs), the rabbit
polyclonal PAN (CO73A), or the rabbit polyclonal specific for
TAp73 isoforms (TA73A) antibodies. CO73A andTA73Awere
produced and purified using a differential purification with
peptides located in theN-terminal part and in the core domain.
Bax was detected with the anti-Bax (N20; Santa Cruz Biotechnol-
ogy, 1:2000) and DR5 with the anti-DR5 (M20; Santa Cruz Bio-
technology, 1:200) antibodies. Actin detection was done with an
anti-actin antibody fromDr. Aunis (Strasbourg, France). Proteins
were then visualizedwith an enhanced chemiluminescence detec-
tion system (Amersham Biosciences).
Real Time PCR—Cells were grown in 6-well plates. After
treatment, cells were harvested, and total RNA was extracted
using a Qiagen kit and treated with DNase (RQ1 RNase-free
DNase, Promega). Reverse transcriptions were performed with
1 g of RNA using the IScript kit (Bio-Rad). The IQ SYBR
Green supermix kit (Bio-Rad) was used for real time PCRs. For
each gene analyzed, a standard curve (from 2 to 0.032 l) was
done with a mix of all RT reactions. Based on this curve, 0.5 l
of RT reaction was analyzed for each condition with all sets of
oligonucleotides (250 nM). Real time PCR protocol included in
all experiments a melting curve that assessed the specificity of
the products. Data were taken in account only if the efficiency
was between 85 and 105% and if the percentage of correlation
(r) was better than 0.995. Real time PCRs and analysis were
performedon an ICycler (Bio-Rad). The following primerswere
used:mouseNp73 (forward, TGCCTGGCCCTGTCTTTG;
reverse, CAG CTC CAGCATGAG TGC); mouse TAp73 (for-
ward, TGG CCT CTC TTG GCC TCC AAC TTG T; reverse,
TTG ACC AGG CCT TGG AGA GCT C); mouse TBP (for-
ward, CTTCGTGCAAGAAATGCTGA; reverse, CCCACC
ATG TTC TGG ATC TT); mouse Noxa (forward, CAG ATG
CCT GGG AAG TCG; reverse, TGA GCA CAC TCG TCC
TTC AA); mouse Bax (forward, ATG CGT CCA CCA AGA
AGC TGA; reverse, AGC AAT CAT CCT CTG CAG CTC C);
mouse DR5 (forward, GTC CAG CTG GCC TAC AGC;
reverse, GCT TGC AGT TCC CTT CTG AC).
CHIPAssay—Cellswere fixedwith 1% (v/v) formaldehyde for
10min at room temperature and quenchedwith 0.125M glycine
for 5 min. ChIP experiments were carried out using the EZ-
Magna ChIPTM chromatin immunoprecipitation kit (Milli-
pore). Sheared cross-linked chromatin from 106 cells was
incubated overnight at 4 °C with 3 g of mouse anti-CHOP
(Santa Cruz Biotechnology) or preimmune mouse IgG (Milli-
pore). Input corresponds to nonimmunoprecipitated sheared
cross-linked chromatin from105 cells (1%). PCR analysis was
performed with 1/25th of immunoprecipitated DNA as tem-
plate and primers of the mouseNoxa promoter (forward, GAA
GTT TCC CTC CCA CCT TC; reverse, GAC GTC ATG TGA
CGA CAT CC).
RESULTS
Neurotoxic Stresses Induce TAp73 and Down-regulate
Np73 Protein Levels—To analyze the potential contribution
of the p73 gene to neuronal apoptosis, we first examined the
expression of its isoforms following neurotoxic treatments in
primary cultures of murine cortical neurons. These neurons
were treated with either the DNA-damaging drug cisplatin,
which causes neuropathy and has already been shown to induce
p73 expression (39, 40), or an antibody that binds to the extra-
cellular part of APP and has been shown to induce neuronal cell
death (41–43). Both of these treatments induced neuronal cell
death as revealed by anMTT test (Fig. 1A) or by detection of the
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active fragment of caspase 3 (p20, Fig. 1B). Under the same
conditions, we monitored byWestern blot the protein levels of
p73 after 1, 6, and 18 h of treatment using new polyclonal anti-
bodies that we had generated to detect the various isoforms of
p73. The antibody TA73A was raised against a peptide located
in the N-terminal part of the TAp73 isoforms. The antibody
CO73A was raised against a peptide sequence of the core
domain of the p73 proteins common to the TA and the N
isoforms (see supplemental data 1). In mouse cortical neurons,
the TA73A antibody detected a signal around 65 kDa corre-
sponding to TAp73, whereas the CO73A antibody revealed a
band migrating slightly below corresponding to Np73 (Fig.
1B and supplemental data 1). The lack of detection of the TA
isoforms by the CO73A antibody might be due to its weaker
sensitivity (as observed with the commercial ER15 antibody)
toward the TA isoforms (supplemental data #1). Other p73 iso-
forms (TAp73, -, and - andNp73), which display notice-
able size difference with TAp73 and Np73, were not
FIGURE 1. Cisplatin and APP alteration induce a shift in p73 isoformprotein levels in cortical neurons leading to the activation of p53 target genes.
A, primary cultures of mouse cortical neurons were treated for the indicated time with cisplatin (Cisp, 20 M) or the APP-directed antibody (APP Ab, 5 g/ml).
Neuronal survival was evaluated using anMTT test. Results are presented in% comparedwith the control condition (Ct). Bars representmeans S.D. of 8wells
fromone experiment out of four independent experiments. The thick black line corresponds to 50%of viability (IC50). B and C, cortical neuronswere treated for
the indicated time with cisplatin (20 M) or the APP Ab (5 g/ml). Cells were lysed, and proteins (75 g) were separated on a 10% SDS-PAGE and immuno-
blottedwith the TA73A, CO73A, actin, p20 (active fragment of Caspase 3), Noxa, DR5, or Bax antibodies.D, cortical neuronswere treated for the indicated time
with the APP Ab (5g/ml). Cells were lysed, and total RNAwere extracted and reverse-transcribed (1g). Quantitative PCR for Noxa, DR5, Bax, and TBP genes
was performed. Bars correspond to means of normalized (TBP) and calibrated (no APP Ab  100) values with standard deviation of triplicates from one
experiment out of three independent experiments. E and F, cortical neurons were transfected with luciferase reporter genes containing either the Bax or the
DR5 promoter. Where indicated, cells were treated with the APP Ab antibody (5g/ml) or cotransfected with expression vectors coding for either APP or PS1
variants (wild type or harboringmutations found in Alzheimer patients). Bars representmeans S.D. (relative light units (RLU)) of 3wells fromone experiment
out of three independent experiments. * indicates statistically significant differences testedby a one-way analysis of variance followedby aNeuman-Keuls test
by pairs (p 0.05).
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detected in mouse cortical neurons, and immunoblotting with
commercial antibodies also suggested that these cells mostly
express the  isoforms of p73 (Fig. 1B and supplemental data).
As reported in cancer cells, cisplatin increased TAp73 protein
levels (44–46). Treatment with the APP-directed antibody also
led to an increase of protein levels of TAp73. In contrast,
Np73 protein levels progressively decreased upon both neu-
rotoxic treatments (Fig. 1B).
This set of experiments indicates that in cortical neurons the
respective levels of the TA and N p73 isoforms are inversely
regulated upon various neurotoxic stresses, including those
associated with neurodegenerative diseases. In addition, the
balance between the p73 isoforms induced (TA) and down-
regulated (N) isoforms shifts toward a probable activation of
the p53/p73 target genes in neurons.
Activation of the APP Pathway Leads to p53/p73 Target Gene
Expression—To test the possibility that a shift between the TA
and the 	 p73 isoforms might lead to the induction of p53/
p73 target genes, we followed the expression of such genes
involved in apoptosis, namely Noxa, Bax, and DR5 (47–49).
Indeed, protein levels as well as mRNA levels of the three genes
progressively increased after treatment with the APP-directed
antibody (Fig. 1,C andD). Transcriptional activities of reporter
genes containing theNoxa,Bax, or theDR5promoter upstream
of the luciferase gene were also stimulated by the APP-directed
antibody (Figs. 1, E and F, and 2A).
APP-dependent neuronal apoptosis has been linked to muta-
tions in theAPPor its processing proteases, the-secretase prese-
nilins (50).Thesemutationshavebeen found inpatientswith early
onset familial Alzheimer disease. To confirm that the alteration of
the APP function leads to activation of these genes, we expressed
in cortical neurons mutated version of the APP (K670N/M67L,
APPSW) andpresenilin 1 (A79V, PS1t) proteins (51). Themuta-
tions correspond to the ones found in familial Alzheimer disease.
As expected, expression of the mutated APP and presenilin pro-
teins induced thepromoter activity ofNoxa,Bax, andDR5 (Figs. 1,
E and F, and. 2A and supplemental data 4). Similar results were
obtainedwithaminimal synthetic reportergene (p53minLuc,Fig.
2C), suggesting that thep53responseelementmediated the induc-
tion seen by alteration of the APP function. Accordingly, no stim-
ulationwas observedwhen the p53-binding sites of theNoxa pro-
moter were mutated (Fig. 2B).
FIGURE 2.Alteration of function of APP leads to induction of Noxa through TAp73. A–C, cortical neurons were transfected with luciferase reporter genes
containing either theNoxapromoter (wild type,noxa Luc;mutated in thep53-binding sites,tnoxa Luc) or a chimerical promoter containingp53-binding sites
(p53RE) in front of the c-fos promoter (p53 min Luc). Where indicated, cells were treated with the APP Ab antibody (5g/ml) or cotransfected with expression
vectors coding for either APP or PS1 variants. Bars represent means S.D. (relative light units (RLU)) of 3 wells from one experiment out of three independent
experiments. D, chromatin immunoprecipitation of p73 on the Noxa promoter. Control () or APP Ab-treated (5 g/ml,) cortical neuron lysates were used
for chromatin immunoprecipitation with control (normal IgG) or TA73A antibodies. Agarose gel showing PCR amplification (35 cycles) of a Noxa promoter
fragment using inputs (1% of chromatin used for ChIP) or ChIPs as templates. E, cortical neurons were transfected with luciferase reporter genes containing
either theNoxa promoter (wild type, noxa Luc;mutated in the p53-binding sites,tnoxa Luc) or a chimerical promoter containing p53-binding sites in front of
the c-fos promoter (p53min Luc). Cells were cotransfectedwith an empty vector (Ct) or with an expression vector coding for TAp73. Bars representmeans
S.D. (relative light units (RLU)) of 3 wells from one experiment out of three independent experiments. F, N2A neuroblastoma cells were transfected with an
empty vector (Ct) or an expression vector encoding TAp73. After 36 h of expression, cells were lysed, and total RNA were extracted and reverse-transcribed
(1g).Quantitative PCR forNoxa,DR5,Bax, and TBPgeneswereperformed.Bars correspond tomeansof normalized (TBP) and calibrated (Ct100) valueswith
standarddeviationof triplicates fromoneexperimentoutof three independentexperiments. * indicates statistically significantdifferences testedbyaone-way
analysis of variance followed by a Neuman-Keuls test by pairs (p 0.05).
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To further confirm that alteration of the APP function in
cortical neurons induced Noxa expression through p73 activa-
tion, we performed chromatin immunoprecipitation assays
using the TA73A antibody. As shown on Fig. 2D, treatment of
cortical neurons with the APPAb led to an increased binding of
TAp73 to the Noxa promoter. The ability of p73 to stimulate
theNoxa, as well asBax andDR5 promoters in cortical neurons
was confirmedbyusing reporter genes or analyses of themRNA
levels (Fig. 2, E and F). Altogether, the data are consistent with
the activation of the Noxa, Bax, DR5 promoters by the APP-
directed antibody being mediated by p73. Thus, the switch of
expression between the p73 isoforms observed upon activation
of the pro-apoptotic APP pathway correlates with the stimula-
tion of the p53/p73-dependent transcription of pro-apoptotic
genes.
TAp73 andNp73 Isoforms RegulateNeuronal Survival—To
evaluate the functional repercussion of the shift between p73
isoforms, we analyzed the ability of these isoforms to regulate
the balance between survival and death in primary culture of
neurons.
The functional impact of TAp73 in neurons was first exam-
ined by overexpression. TAp73 was coexpressed with GFP to
specifically monitor the morphology (fragmentation or con-
densation of the nucleus and integrity of the neurites) of the
transfected cells. Overexpression of TAp73 in cortical neu-
rons induced nuclear changes indicative of neuronal cell death
(Fig. 3, A–C). Concomitant pro-neurotoxic treatment of the
neurons with the APP-directed antibody or cisplatin further
increased cell death (Fig. 3D and supplemental data 4).
To assess if a TAp73 isoform contributes to the apoptosis
induced by the APP-directed antibody or cisplatin in cortical
neurons, we used siRNA to specifically silence TAp73 expres-
sion (Fig. 3D). The inset in Fig. 3D shows the knockdown of
TAp73 expression obtained by the transfection of two different
TAp73 siRNA duplexes. Apoptosis induced by the APP-di-
rected antibody or cisplatin was partially blocked by the silenc-
FIGURE 3. TAp73 induces pro-apoptotic gene expression and neuronal apoptosis. A–D, cortical neurons were transfected with a GFP expression vector
and either with the TAp73 expression vector or TAp73 siRNA duplexes (siTAp73#1 or siTAp73#2). After 24 h, cells were left untreated (Ct) or treated with APP
Ab (5 g/ml) or cisplatin (Cisp) (20 M) for 24 h. Cells were then fixed, stained with Hoechst, and observed with a fluorescence microscope. A shows two
GFP-positive control cells (untreated). B shows a deadGFP-positive cell treatedwith APPAb.C shows a dead cortical neuron transfectedwith TAp73.D, graph
represents the percentage of dead cells among the GFP-positive cells counted. Bars correspond to means of three wells of a representative experiment with
S.D. The inset illustrates the silencing of TAp73 by TAp73 siRNAs (Western blot with TA73A and actin antibodies). E, cortical neurons were cotransfected with
the noxa Luc reporter construct and either control (siCt) or TAp73 siRNAs for 36 h. Then cells were treated with APP Ab for 8 h or not (Ct). The siRNA
concentration used was 40 nM. Bars represent means S.D. (relative light units (RLU)) of 3 wells from one experiment out of three independent experiments.
* indicates statistically significant difference tested by a one-way analysis of variance followed by a Neuman-Keuls test by pairs (p 0.05).
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ing of TAp73 expression (Fig. 3D). In addition, silencing of
TAp73 by siRNA significantly reduced the stimulation of the
Noxa reporter construct caused by the APP-directed antibody
(Fig. 3E). Thus, neuronal apoptosis induced by alteration of the
APP function is partially achieved through stimulation of pro-
apoptotic genes that are regulated by an increased level of
TAp73.
We used similar approaches to assess the role of Np73 in
neuronal survival. In contrast with TAp73, overexpression of
Np73 significantly reduced the apoptosis of cortical neurons
obtained by cisplatin, treatmentwith theAPPAb, or expression
of mutated APP or presenilin 1 (Fig. 4A). Note that as observed
previously (52), overexpression of wild type APP induced also a
slight increase in neuronal cell death. In cortical neurons, apo-
ptosis induced by cisplatin or excitotoxic stress induced by glu-
tamate was also decreased upon overexpression of Np73
(Fig. 4B). In addition, overexpression of Np73 significantly
reduced the activity of theNoxa reporter gene generated by the
mutated forms of APP or presenilin 1 (Fig. 4C).
Taken together these observations indicate that in cortical
neurons the TA andN isoforms of p73 exert opposite effects
on neuronal apoptosis in response to alteration ofAPP function
or other neurotoxic stresses. The induced expression of TAp73
isoforms could account for part of the neuronal cell death
caused by activation of the APP pathway. On the contrary,
Np73 exerts protective effect against various neurotoxic
stresses.
Neurotoxic Stresses Increase Both TAp73 and Np73 mRNA
Levels—To analyze the molecular mechanisms leading to
changes in the protein levels of p73 isoforms, wemonitored by
real time PCR the mRNA levels of TAp73 and Np73 after
activation of the APP pathway in cortical neurons (Fig. 5,A and
B). As expected from the protein data, mRNA levels of TAp73
isoforms were augmented by the APP-directed antibody, sug-
gesting a regulation at the promoter level. The mRNA levels of
Np73 isoformswere also increased, which contrastedwith the
data obtained by Western blot (Fig. 1B).
To confirm the regulation of p73 expression by transcrip-
tional mechanisms, we used a luciferase reporter gene con-
trolled by the p73 promoter (53). Treatment with the APP-
directed antibody, overexpression of amutated form of APP, or
a mutated PS1 led to a stimulation of the p73 promoter activity
(Fig. 5C). Interestingly, overexpression of the cytoplasmic
AICD fragment of APP or the APP cofactor FE65 also stimu-
lated the activity of the p73 promoter.
These results suggest that the increase of TAp73 protein
levels upon neurotoxic stresses is mediated through transcrip-
tional activation of the p73 promoter. However, in the case of
Np73, the regulation at the mRNA level could not explain
the disappearance of Np73 proteins after neurotoxic
treatments.
APP Signaling and Neurotoxic Stresses Induce the Degrada-
tion of Np73 through Multiple Proteases—To understand
the mechanisms involved in the down-regulation of the
Np73 proteins that contrasted with the stimulation at the
mRNA level, we tested the possibility that Np73 proteins
could be degraded in the course of neural apoptosis. To this
end, neurotoxic treatments were performed in the presence of
various proteases inhibitors that were found to be involved in
neuronal apoptosis (54). As shown in Fig. 6A, Np73 protein
level in cortical neurons slightly increased in the presence of
FIGURE 4. Overexpression of Np73 antagonizes neuronal apoptosis
induced by various kinds of neurotoxic stresses. A and B, cortical neurons
were cotransfectedwith the indicated combinationofNp73,mutatedAPP
(APP SW), or mutated presenilin 1 (Prest) and GFP expression vectors. After
24 h of expression, cells were left untreated (Ct) or treated with APP Ab (5
g/ml), cisplatin (Cisp, 20 M) or glutamate (Glu, 250 M) for 24 h. Cells were
then fixed, stained with Hoechst, and observed with a fluorescence micro-
scope. Bars represent the percentage of dead cells among the GFP-posi-
tive cells counted. Bars are means of 3 wells of a representative experi-
ment with S.D. C, cortical neurons were cotransfected with the noxaLuc
reporter gene and the indicated combination of TAp73, Np73,
mutated APP, or mutated presenilin 1 expression vectors. Bars represent
means S.D. (relative light units (RLU)) of 3 wells fromone experiment out
of three independent experiments. * indicates statistically significant dif-
ferences tested by a one-way analysis of variance followed by a Neuman-
Keuls test by pairs (p  0.05).
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caspases (VAD) and proteasome (ALLN) inhibitors. More
strikingly, these inhibitors reversed in part the loss of Np73
caused by theAPP-directed antibody as shown by the increased
difference between control and theALLNorVADconditions in
presence of APP Ab (Fig. 6A and supplemental data 3).
To dismiss the possibility that the increase in Np73 pro-
tein levels was due to an indirect effect of these protease inhib-
itors, we tested their ability to antagonize the degradation of
Np73 protein in vitro. Np73 was expressed in the N2A
cell line and immunoprecipitated. After multiple washes, the
immunoprecipitated Np73 was incubated with various cel-
lular extracts in the presence or absence of protease inhibitors.
Extracts from cortical neurons treated by the APP-directed
antibody or cisplatin induced the degradation of the immuno-
purified Np73 proteins (Fig. 6B and supplemental data 3).
Remarkably, addition of the caspase inhibitor or the protea-
some inhibitor reversed this degradation. These results demon-
strate that the diminution of Np73 protein levels observed
after neurotoxic treatments resulted from a degradation
induced by multiple proteases.
Neurotoxic Stress-induced Degradation of Np73 Depends
on Phosphorylation of Thr-86 by JNK and CDK—Protein deg-
radation is often controlled by phosphorylation events, as has
been shown for p53. In previous studies (33), we have found
that the TAp73 proteins can be phosphorylated at Thr-86 by
CDKs. This phosphorylation site is also present in Np73 iso-
forms. Given that CDK have been implicated in neural cell
death (55), we hypothesized that neurotoxic stresses may
induce CDK activity leading to phosphorylation of Np73 at
Thr-86, as this site is conserved between human and mouse,
and between TA and N isoforms (Fig. 6C).
We first analyzedwhether Thr-86 ofNp73 could be phos-
phorylated in vitro by CDKs. For this, Np73 was immuno-
precipitated from transfected N2A cells and then incubated
with a purified cyclin A-CDK1 complex. Western blot analysis
using an antibody specifically directed against p73 proteins
phosphorylated at Thr-86 indicated Thr-86 phosphorylation
for wild type Np73 but not for a T86A mutant of Np73
(Fig. 6D). Of note, Np73 in vitro phosphorylation at Thr-86
by cyclin A/CDK1 appeared stronger than that of TAp73.
Next, we verified thatNp73was the target of CDKs in intact
N2A cells. Np73 was coexpressed with various CDK com-
plexes, including CDK5 that has been extensively studied for its
role in Alzheimer disease (56). As we have already shown for
TAp73, CDK complexes containing cyclin A or B associated
withCDK1 orCDK2 phosphorylatedNp73 (Fig. 6E). In con-
trast, complexes containing cyclin E orD associatedwithCDK4
did not. Finally, we found that CDK5 and JNK were able to
induce substantial phosphorylation of Thr-86 (Fig. 6E). Thr-86
is also located in a potential JNK phosphorylation site, and the
importance of JNK in neuronal apoptosis has been largely dem-
onstrated (57). In particular, we have shown that JNK is amedi-
ator of the cell death induced by the APP-directed antibody
(43).
Next, we monitored the Thr-86 phosphorylation status of
endogenous Np73 in cortical neurons submitted to various
neurotoxic stresses. p73 proteins were immunoprecipitated
and analyzed by Western blot using the phosphospecific
FIGURE 5. Neurotoxic stresses induce both TAp73 and Np73 isoforms
mRNAs. A and B, cortical neurons were left untreated (Ct) or treated with the
APP Ab (5 g/ml), cisplatin (Cisp, 20 M) or glutamate (Glu, 250 M) for the
indicated timebefore preparationof totalmRNAs. After reverse transcription,
real time PCRs were performed using TBP and either Np73 (A) or TAp73 (B)
isoform-specific primers. For standardization, TBP values were used. Graphs
represent the percentage of induction relative to the control condition (Ct).
Bars are means of three wells of a representative experiment with S.D.
C, cortical neurons were transfected with the p73-Luc reporter construct
along with different expression vectors (empty, Ct; encoding APP, wild type
(APP), mutated as in Alzheimer patients (APPSW) or the AICD cytoplasmic
fragment (AICD); encoding the APP cofactor FE65 (FE65)) or treated with the
APP-directed antibody (5 g/ml). Graphs represent means  S.D. (relative
light units (RLU)) of 3 wells from one experiment out of three independent
experiments. * indicates statistically significant differences (analysis of vari-
ance, Neuman-Keuls multiple comparison test, p 0.05).
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Thr-86 antibody. As shown in Fig. 6F, treatment with the APP-
directed antibody or other neurotoxic treatment (cisplatin or
glutamate) increased Thr-86 phosphorylation. Using specific
kinase inhibitors, we then determined whether CDKs or
JNKs were involved in Thr-86 phosphorylation. Both inhib-
itors led to a significant but partial reversion of the Thr-86
phosphorylation induced by neurotoxic stresses, suggesting
that both types of kinases target this site in neurons (Fig. 6G).
Taken together, these data suggest that increased Thr-86
phosphorylation of Np73 by CDKs and JNKs upon neu-
rotoxic stress enhances its degradation through caspases or
the proteasome pathway.
Phosphorylation of Thr-86 Regulates the Stability Np73
and Modulates Its Neuroprotective Effect—To test the impor-
tance of the phosphorylation of Np73 at Thr-86, we com-
pared the activity ofwild type andmutantT86ANp73on the
p53min luciferase reporter gene.Overexpression ofTAp73 or
mutant APP induced the activity of this reporter gene in corti-
cal neurons (Fig. 7B). This activationwas inhibited by coexpres-
sion of Np73. Interestingly, the T86A mutant Np73 dis-
played a more robust inhibition than wild type Np73 (Fig.
7B).When we studied the relative protein levels of theNp73
variants, we observed that the mutant T86A was expressed at a
slightly higher level (Fig. 7A). From these results, we hypothe-
sized that the stability of the T86A mutant could be different
from the wild type. Therefore, we tested the sensitivity of wild
type and T86A mutant Np73 toward extracts from cortical
neurons treated with the APP-directed antibody. As observed
in Fig. 7A, extracts from neurons treated with neurotoxic
stresses induced the degradation of wild type Np73. In con-
trast, the T86A mutant was significantly more resistant (Fig.
7A).
We further analyzed the physiological relevance of the JNK
and CDK-dependent phosphorylation of Np73 at Thr-86 by
testing its ability to rescue neurons fromcell death.Wild type or
T86A Np73 proteins were coexpressed with GFP in cortical
FIGURE 6.Neurotoxic stresses lead toNp73 degradation by proteases and phosphorylation at threonine 86. A, cortical neuronswere left untreated or
treated for 18 h with APP Ab (5g/ml) in the presence or absence of protease inhibitors (VAD, 50M; PS1, 25M; ALLN, 15M). Cells were lysed, and proteins
(75g)were separatedona10%SDS-PAGEand immunoblottedwith thep73CO73Aandactin antibodies.B,overexpressedNp73was immunoprecipitated
from N2A protein extracts and incubated with extracts of cortical treated with the APP-directed antibody (APP Ab, 5 g/ml) or cisplatin (Cisp, 20 M) in the
presence or absence of protease inhibitors. Proteinswere then separated on a 10%SDS-PAGE and immunoblottedwith anHA-directed antibody.C, schematic
representation and comparison between mouse and human sequences for TAp73 and Np73. D, TAp73 wild type, TAp73 mutated in the Thr-86 site
(TAp73T86A), Np73wild type, and Np73mutated in the Thr-86 site (Np73T86A) were expressed in N2A cells. Proteins were extracted with a TEGN
buffer containingnophosphatase inhibitor, andp73proteinswere immunoprecipitated asdescribed. Immunoprecipitatedp73proteinswere submitted to an
in vitro kinase assay using a purified cyclin A-CDK1 complex (CACDK1) before SDS-PAGE and successive immunoblotting with the phospho-specific Thr-86
antibody (Thr-86, lower panel) and the HA antibody (upper panel) to detect the level of immunoprecipitated p73 proteins. E,N2A cells were cotransfectedwith
HA-Np73, cyclin D (CD), and CDK4, cyclin B (CB), and CDK1, CDK5, or JNK expression vectors as indicated. HA-immunoprecipitated p73 proteins were
separated by SDS-PAGE and successively immunoblotted with the anti-phospho-Thr-86 antibody (Thr-86, upper panel) and the HA antibody (lower panel).
F and G, cortical neurons were treated with the APP-directed antibody (APP Ab, 5 g/ml), cisplatin (Cisp, 20 M), or glutamate (Glu, 250 M) for 24 h.
Co-treatments with CDK inhibitor (roscovitine, 5 M) or JNK inhibitor (PB1557, 5 M) was performed in G. p73 proteins were immunoprecipitated from the
protein extract (2 mg) using the COP73A p73 antibody, separated by SDS-PAGE, and successively immunoblotted using the anti-phospho-Thr-86 antibody
(Thr-86, upper panel) and the COP73A antibody (Np73, lower panel) to check the levels of immunoprecipitated p73 proteins. Images presented are from a
representative experiment out of at least three independent experiments.
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neurons treated with the APP-directed antibody. GFP-positive
cells were observed, and cell death was assessed on the mor-
phology of the nucleus and the neurites. As illustrated in Fig.
7C, overexpression of wild type Np73 partially rescued neu-
rons from apoptosis induced by the APP-directed antibody
(Fig. 7C). However, the rescue induced by the T86A Np73
variant was more pronounced, confirming the importance of
the Thr-86 phosphorylation site for regulation of the function
of Np73 in neurons.
DISCUSSION
Neuronal cell death is a cellular fate inherent to the develop-
ment of an integrated neural network, but it may however also
be inadequately activated by multiple stresses associated with
neurodegenerative disorders such as Alzheimer, Parkinson,
ALS, etc. Several keymolecular mechanisms that relay external
stresses or genetic alterations and generate neuronal cell death
have been identified. They involve several specific pathways
such as JNK/c-Jun, CDKs/E2F1, or p53, which often induce
caspase 3 cleavage and nucleus alterations. The elucidation of
these signaling pathways is a necessary step to design highly
specific and efficient therapies against neurodegenerative dis-
orders. However, it is still extremely difficult to have a precise
and complete scheme on how each individual stress among
their vast diversity is linked to specific apoptotic mechanisms.
In this study, we have investigated in detail the contribution of
p73 to neuronal cell death induced by several kinds of neuro-
toxic stresses in cortical neurons. We have also identified
mechanisms that regulate the expression and the activity of
several p73 isoforms harboring opposite functions. Our results
indicate a convergence of various neurotoxic stresses toward
commonmolecularmechanisms that affect p73 expression and
might therefore represent interesting therapeutic targets.
p73, Ying and Yang in Neuronal Apoptosis?—Altogether, our
data showed interesting opposite regulations and effects during
neuronal survival for TAp73 and Np73, which highlight the
essential role of p73 in the CNS. This role was already seen in
the p73 knock-out mice that have neurological defects (17) but
was mainly attributed to Np73 isoforms. However, as all iso-
forms were inactivated through this approach, the interpreta-
tions about the respective role of TA and N isoforms were
limited de facto. Furthermore, a possible compensation by the
othermembers of the p53 family, p53 and p63, might also com-
plicate the understanding of the role of each individualmember
in neuronal apoptosis. Recently, such complexity was further
illustrated through the realization of Np73 transgenic mice
that display more severe embryonic defects than the individual
p53, p73, or p63 knock-outmice (58). Therefore, in vitro studies
performed with primary cultures of neurons are useful to deci-
pher the intricate roles of the p53 family members.
Our analysis of p73 expression in cortical neurons clearly
showed that TAp73 and Np73 isoforms were coregulated,
with the ratio of both types of isoforms depending on the phys-
iological conditions (Fig. 1). The expression level was regulated
by diverse apoptotic conditions such as DNA damages (cispla-
tin) or alterations of the APP pathway (Fig. 1), leading to
increased expression of p53/p73 target genes, such as Noxa
(Figs. 1 and 2). This regulation suggested that both Np73 and
TAp73 were playing a role in neuronal survival. Indeed, over-
expression of TAp73 induced apoptosis, although Np73 was
protecting neurons from stresses (Figs. 3 and 4).
The neuroprotective role of Np73 might be linked to the
inactivation of p53, as reported previously for the survival of
derived root ganglia neurons following NGF treatment (24) or
CNS neurons (25). This study shows that TAp73 isoforms are
FIGURE7.Thr-86phosphorylation regulatesanddestabilizesNp73pro-
teins. A, overexpressed Np73 and Np73T86A were immunoprecipi-
tated from N2A cellular extracts and incubated with extracts of cortical neu-
rons left untreated (Ct), treated with the APP-directed antibody (APP Ab, 5
g/ml), or cisplatin (Cisp, 20 M). Proteins were then separated on a 10%
SDS-PAGE and immunoblotted with a p73 antibody. B, cortical neurons were
cotransfectedwith the p53min luciferase reporter construct, and the expres-
sion vectors coding for APP SW, TAp73, and Np73 (wild type or T86A
mutant) as indicated. Bars represent means S.D. (relative light units (RLU))
of 3 wells from one experiment out of three independent experiments.
C, cortical neurons were cotransfected with combination of Np73 or
Np73T86A andGFP expression vectors. After 24 h of expression, cells were
treated with APP Ab (5 g/ml) for 24 h. Cells were then fixed, stained with
Hoechst, andobservedwith a fluorescencemicroscope.Graphs represent the
percentage of apoptotic cells among the GFP-positive cells counted. Bars are
means of three wells of a representative experiment with S.D. * indicates
statistically significant differences (analysis of variance, Neuman-Keuls Multi-
ple comparison test, p 0.05).
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expressed and play a role in cortical neuron apoptosis in
response to alteration of the APP pathway or DNA damages,
indicating that Np73 can also exert its neuroprotective activ-
ity by inhibiting TAp73 isoforms. Furthermore, recent studies
have also shown that p63 is involved in other neurotoxic stress
responses in cortical neurons, such as ischemia (26). Therefore,
the situation in cortical neurons is rather complex, and the
exact role of each p53 family member remains to be established
because they potentially share similar cellular functions and
target genes. In vivo functional studies using appropriate trans-
genic animals, as well as the precise identification of the specific
pool of target genes regulated by each p53 protein in specific
neurotoxic conditions, would bring crucial information for
understanding the respective role of each member. The molec-
ular mechanism of the dominant negative activity of Np73
also remains to be determined. Obviously, Np73 might
repress some pro-apoptotic p53 family members through het-
erodimerization, as described for TAp73 and p63 (59), which
still remains controversial for p73 and wild type p53 (59).
Another possibility is that Np73 exerts its dominant negative
activity through the competition for p53-binding sites. How-
ever, the fact that the various p53 family members display dif-
ferent binding affinities might limit the dominant negative
effect ofNp73 on p53 target genes (60). Alternatively, the high
level ofNp73 proteins might have an effect on its own, target-
ing a specific subset of genes linked to neuronal survival.
Finally, it is important to note that Np73 did not rescue all
neurons from apoptosis, even if a significant proportion was
protected. The death of these unprotected neurons might be
attributed to the limit of the experimental approach that did not
allow an accurate correlation between the expression level of
Np73 expression in eachneuron and its fate.Obviously, itmay
also correspond to the involvement of mechanisms indepen-
dent of p53 family members.
Conversely, we found that TAp73 was important for cispla-
tin- and APP-induced neuronal cell death (Fig. 3). Overexpres-
sion of TAp73 induced apoptosis, whereas siRNAs that knock
down specifically TAp73 isoforms partially rescued neurons
from apoptosis (Fig. 3). Furthermore, we identified pro-
apoptotic genes that were up-regulated by TAp73 in cortical
neurons, namelyNoxa,Bax andDR5 (Fig. 1). This indicates that
TAp73 can directly regulate the expression of genes linked to
cell death in neurons (61, 62). These genes are also targeted by
p53 and might therefore be coregulated by p53 and TAp73 in
neuronal stress conditions that induce both transcription fac-
tors, such as APP stimulation, DNA damage, or neurotoxic
stress (Figs. 1 and 3) (30, 49). Nevertheless, our data about
TAp73 provide some molecular explanations to the observa-
tion that p73 proteins are induced in neurons of Alzheimer
patients (27, 28).
Regulation of p73 Isoforms in Neurons—We found that the
protein levels of TAp73 andNp73were oppositely affected by
neurotoxic stresses (Figs. 1 and 3). The molecular mechanisms
involved were different for both types of isoforms.
TAp73 expression was increased at both the protein and the
mRNA levels (Figs. 1, 3, and 5), suggesting that its expression
was partially regulated through its promoter. Indeed, we found
that the APP pathway activated the p73 promoter (Fig. 5). The
transcription factors involved remain to be identified, but one
possible player is E2F1 as its expression is induced by the-am-
yloid peptide (63).
Our analysis of Np73 expression revealed a post-transla-
tional mechanism. Inhibitors of calpain, caspases, and protea-
some rescued the loss of Np73 expression after neurotoxic
treatments. All three kinds of proteases played a role, but the
proteasome and the caspases seemed to be predominant (Fig.
6). These proteases have beendescribed for their important role
in neuronal apoptosis (54). Calpain cleavage and proteasome-
dependent degradation of p73 have already been described and
might account for the regulations we observed here (64–66). It
remains to be established whether these mechanisms are
recruited in neurons to directly degrade Np73 or if specific
neuronal cofactors, such as ubiquitin ligases, step in.
The degradation of Np73 was tightly controlled by phos-
phorylation at threonine 86 (Fig. 6). Neurotoxic stresses
induced this phosphorylation through JNK and CDK (Fig. 6).
These kinases (especially CDK5 and JNK)were frequently asso-
ciated with neuronal apoptosis and Alzheimer disease (41, 56,
57). The exactmechanisms that linkThr-86 phosphorylation to
Np73 degradation remain to be established. These mecha-
nismsmay involve changes inNp73 protein conformation, its
localization, or its association with partner proteins that con-
trol its degradation.
It is likely that additional post-translational modifications,
such as other phosphorylation, acetylation, sumoylation, or
isomerization by Pin1, participate in the control of Np73 and
TAp73 activity and stability during neuronal cell death (67, 68).
In particular, the tyrosine kinase c-Abl could be an interesting
candidate as it has been shown to phosphorylate and stabilize
TAp73 (44) and has also been proposed to play a role in tauopa-
thies and Alzheimer disease (69). Additional studies will allow
us to further detail the cascades of events that link p73 to neu-
ronal cell death and in association with neurodegenerative
diseases.
p53 Family and Neurodegenerative Diseases—Our results
showa significant role of thep73 gene in the control of neuronal
fate, with TAp73 being a neuronal cell death mediator, al-
though Np73 has an interesting potential for rescuing neu-
rons from various stresses. p73 appears to be a sensor of various
neurotoxic stresses, making it an ideal intracellular relay for
genetic or sporadic neurodegenerative diseases. In particular,
we have shown that alteration of the APP pathway using APP
Ab or mutated APP leads to changes in p73 isoform expression
(Fig. 1). Moreover, silencing of TAp73 reduced the neurotoxic
effect of APP signaling pathway alteration (Fig. 3). Even if the
exact APP processing cascade involved in these observations is
not yet clear, these data support previous observations. Indeed,
p73 expression is increased in the brain of Alzheimer patients
(27, 28), but as p53 and p63 are also involved in neuronal fate
(30, 70, 71), itmight not be the onlymember of the p53 family to
be involved in neurodegenerative diseases. p53 has already been
associated with several neurodegenerative disorders such as
ALS (72), Alzheimer (15), HIV-mediated dementia (73), or Par-
kinson (74). In particular, the AICDdomain of APP that can act
as a transcription factor (75) has been shown to regulate p53
(76). The transcriptional activity of the AICD might also
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explain the ability of an altered APP signaling pathway to reg-
ulate the p73 promoter (Fig. 5). Several key questions remain
unanswered, such as whether p53 family members share com-
mon target genes orwhether they interact in specific physiolog-
ical situations. However, our study shows that deleterious
neurodegenerative-associated mechanisms can be reduced
through a modulation of the p53-like dependent function,
which suggests that the p53 family represents in its whole a
potential target for a therapeutic approach against neurodegen-
erative diseases.
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